Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-10-24
2006-10-24
Kaushal, Sumesh (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S001000, C514S002600, C435S243000, C435S253100, C424S093100, C536S023100
Reexamination Certificate
active
07125858
ABSTRACT:
The present invention relates to a composition and method comprising purified HA, a second anti-neoplastic agent and a pharmaceutically acceptable carrier, wherein the purified HA and the second anti-neoplastic agent are administered to a mammal having cancer in an amount effective to treat the cancer.
REFERENCES:
patent: 3172815 (1965-03-01), Fox et al.
patent: 3976544 (1976-08-01), Adam et al.
patent: 4010257 (1977-03-01), Adlam et al.
patent: 4036953 (1977-07-01), Adam et al.
patent: 4152423 (1979-05-01), Adam et al.
patent: 4182751 (1980-01-01), Ayme
patent: 4337243 (1982-06-01), Ayme
patent: 4520019 (1985-05-01), Ribi et al.
patent: 4579941 (1986-04-01), Furutani et al.
patent: 4647456 (1987-03-01), Pulverer
patent: 4663306 (1987-05-01), Cantrell
patent: 4724144 (1988-02-01), Rook et al.
patent: 4726947 (1988-02-01), Shimada et al.
patent: 4744984 (1988-05-01), Ragland
patent: 4877611 (1989-10-01), Cantrell
patent: 5759554 (1998-06-01), Alkemade et al.
patent: 5827834 (1998-10-01), Falk et al.
patent: 5888986 (1999-03-01), Morales et al.
patent: 6326357 (2001-12-01), Phillips et al.
patent: 6329347 (2001-12-01), Phillips et al.
patent: 6475795 (2002-11-01), Turley et al.
patent: 0 158 075 (1985-02-01), None
patent: 0 308 197 (1988-09-01), None
patent: 0 343 480 (1989-05-01), None
patent: WO 87/02679 (1987-05-01), None
patent: WO 94/16727 (1994-08-01), None
patent: WO 94 20115 (1994-09-01), None
patent: WO 95 30423 (1995-11-01), None
patent: WO 97/33612 (1997-09-01), None
patent: WO 98 17320 (1998-04-01), None
patent: WO/9817320 (1998-04-01), None
patent: WO 99 02151 (1999-01-01), None
patent: WO 99/07383 (1999-02-01), None
patent: WO 99/42113 (1999-08-01), None
patent: WO 00/33875 (2000-06-01), None
patent: WO 00 41730 (2000-07-01), None
patent: WO 00/56269 (2000-09-01), None
Hode-Dufour et al J. Immunology 159:2492-2500, 1997.
Vincent et al J. Biol.Chem. 276(18):14728-14736, 2001.
Gomez-Navarro et al, Eur. J. Cancer. 35(6);867-885, 1999.
Freemantle, C., et al., “The Modulation of Granulomatous Tissue and Tumour Angiogenesis by Diclofenac in Combination with Hyaluronan (Hyal Ex-0001),”Int. J. Tiss. Reac., vol. XVII (4), pp. 157-166 (1995).
V. Assmann, et al., “The Human Hyaluronan Receptor RHAMM is Expressed as an Intracellular Protein in Breast Cancer Cells,” Journal of Cell Science 111, pp. 1685-1694 (1998).
H. Brem, M.D., et al., “Interstitial Chemotherapy with Drug Polymer Implants for the Treatment of Recurrent Gliomas,” J. Neurosurg, vol. 74, pp. 441-446 (Mar. 1991).
G. P. Dimri, et al., “A biomarker that Identifies Senescent Human Cells in Culture and in Aging SkinIn Vivo, ” Proc. Natl. Acad. Sci. USA, vol. 92, pp. 9363-9367 (Sep. 1995).
Eck et al., “Goodman & Gilman's The Pharmacological Basis of Therapeutics,” Chap. 5: Gene-Based Therapy, McGraw-Hill, New York, p. 77-101, dated 1996.
Filion, M.C. et al., “Mycobacterial Cell Wall—DNA Complex Induces Apoptosis in Cancer Cells,”J. Pharm. Pharmacol., vol. 50 (Supplement), p. 39 (1998).
Filion, M.C. et al., “Mycobacterial Cell Wall-DNA Complex (MCC) Induces Cell Cycle Arrest at the Late S+G2M Phase in Leukemic Cells,” British Journal Of Cancer, GB, London, vol. 80, No. Suppl. 02, Jul. 1999, p. 76, XP000892420 (Abstract).
Filion M. C., et al., “Mycobacterial DNA Induces Apoptosis in Myeloid Leukemia Cell Lines,” 39thAnn. Mtg. Amer. Soc. Herm., Dec. 1997 (Abstract).
Filion M.C., et al.; “Mycobacterium phleiCell Wall Complex, a New Anti-Tumoral Agent, Induces IL-12 Synthesis by Monocyte-Macrophages via Associated DNA,” 39thAnn. Mtg. Amer. Soc. Herm. Dec. 1997.-*
Filion, M.C., et al., “Mycobacterium phleiCell Wall Complex, a New Anti-Tumoral Agent, Induces IL-12 Synthesis by Monocyte/Macrophages via Associated DNA,” Blood, Nov. 15, 1997, p. 58b (2859), vol. 90, No. 10, Suppl. 1. (Abstract).
Filion, M.C. et al., “Mycobacterium phleiCell Wall Complex Directly Induces Apoptosis in Human Bladder Cancer Cells,”British J. of Cancer, vol. 79, No. 2, pp. 229-235 (1999).
Filion, et al., “Toxicity and Immunomodulatory Activity of Liposomal Vectors Formulated with Cationic Lipids Toward Immune Effector Cells,” Biochim Biophys Acta, 1997, 345-356, vol. 1329.
Gray, G.R., et al., “Brief Communication: Immunotherapy of Cancer: Tumor Suppression and Regression by Cell Walls ofMycobacterium phleiAttached to Oil Droplets,”J. Natl. Cancer Instit., vol. 55, No. 3, pp. 727-730 (Sep. 1975)
Kataoka T., et al., “Antitumor Activity of Synthetic Oligonucleotides with Sequences from cDNA Encoding Proteins ofMycobacterium-BovisBCG”,JPN J. Can. Res., vol. 83, No. 3, pp. 244-247, 1992.
Kishore et al., “Induction of Cell Mediated Immune Response by Nonspecific Stimulator of Immunity Against Antigenically Unrelated Oncogenic Virus,” (Marek's disease virus) Indian Journal or Experimental Biology, vol. 27: 529-531 (Jun. 1989).
Klinman, D.M. et al., “CpG Motifs Present in Bacterial DNA Rapidly Induce Lymphocytes to Secrete Interleukin 6, Internleukin 12, and Interferon γ,”Proc. Natl. Acad. Sci. USA, vol. 93, pp. 2879-2883 (Apr. 1996).
Mallick et al., “Nonspecific Immunostimulation Against Viruses,” Comp. Immun. Microbiol. Infect. Dis. vol. 8(1):53-63 (1985).
Mashiba H., et al., “In-vitro Augmentation of Macrophage-Activating-Factor Release from Peripheral Blood Cells of Cancer Patients by a DNA Fraction fromMycobacterium bovisBCG,” Japanese Journal of Medical Science and Biology, Aug. 1990, 43 (4) 133-9, Journal Code: KLZ. ISSN: 0021-5112, XP002085536.
E. Marshal, Science vol. 269, p. 1052-1053 (Aug. 1995).
C. M. McKee, et al., “Hyaluronan Fragments Induce Nitric-oxide Synthase in Murine Macrophages through a Nuclear Factor KB-dependent Mechanism,” JBC Online, The American Society for Biochemistry and Molecular Biology, Inc., vol. 272, No. 12, pp. 8013-8018 (Mar. 21, 1997).
C. M. McKee, et al., “Hyaluronan (HA) Fragments Induce Chemokine Gene Expression in Alveolar Macrophages,” J. Clin. Invest., The American Society for Clinical Investigation, Inc., vol. 98, No. 10, pp. 2403-2413 (Nov. 1996).
Morales, A., et al., “Immunotherapy of an Experimental Adenocarcinoma of the Prostate,”J. of Urology, vol;. 153, pp. 1706-1710 (May 1995).
Ossina et al., “Interferon-Gamma Modulates a P53-Independent Apoptotic Pathway and Apoptosis Related Gene Expression,” J. Biol. Chem. vol. 272(26): 16351-16357 (Jun. 27, 1997).
Pisetsky, D.S., et al., “Immune Activation by Bacterial DNA: A New Genetic Code,”Immunity, vol. 5, pp. 303-310, (Oct. 1996).
Pisetsky, D.S., et al., “Stimulation ofIn VitroProliferation of Murine Lymphocytes by Synthetic Oligodeoxynucleotides,”Mol. Biol. Reports, vol. 18, pp. 217-221 (1993).
Phillips, et al., “Influence of Phospholipid Compositions on Antibody Responses to Liposome Encapsulated Protein and Peptide Antigens,” Vaccine, pp. 898-904, vol. 14, No. 9 (1996).
Reader, S., et al., “Mycobacterial Cell Wall-DNA Complex (MCC) Inhibits Proliferation and Induces Apoptosis in Androgen-Dependent and Independent Human Prostate Cancer Cells,” British Journal of Cancer, p. 190, vol. 80, No. 2 (Jul. 1999) (Abstract).
Rojas M., et al., “Differential Induction of Apoptosis by VirulentMycobacterium tuberculosisin Resistant and Susceptible Murine Macrophages: Role of Nitric Oxide and Mycobacterial Products”,J. of Immun., vol. 159, No. 3, pp. 1352-1362, (Aug. 1997).
G. R. Screaton, et al., “Genomic Structure of DNA Encoding the Lymphocyte Homing Receptor CD44 Reveals at Least 12 Alternatively Spliced Exons”, Proc. Natl. Acad. Sci. USA, vol. 89, pp. 12160-12164 (Dec. 1992).
Shimada S., et al., “Antitumor Activity of the DNA Fraction fromMycobacterium bovisBCG. II. Effects on Various Syngeneic Mouse Tumors”;J. of Nat. Can. Inst., vol. 74, No. 3, pp.
Filion Mario C.
Phillips Nigel C.
Bioniche Life Sciences Inc.
Kaushal Sumesh
Kilpatrick & Stockton LLP
LandOfFree
Hyaluronic acid in the treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hyaluronic acid in the treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hyaluronic acid in the treatment of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3658126